BRIGHT MINDS BIOSCIENCES INC. (DRUG)
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Bright Minds Biosciences Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 9.86M shares outstanding
CABright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases.
Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin.
The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Leadership
Garry Wong
Chief Financial Officer
Maggie Deng
Chief Operating Officer
Yanlin Han
Chairman and Chief Executive Officer
Zhanguo Weng
Vice President, China Operations
Employees
26
Country
CA
Sector
Healthcare
Website
brightmindsbio.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Cormorant Asset Management, LP | -- | Sale | 109.3K | $9.79M | Apr 28, 2026 |
| Cormorant Asset Management, LP | -- | Purchase | 184.3K | $4.00M | Nov 4, 2024 |
| Cormorant Asset Management, LP | -- | Purchase | 39.7K | $922.6K | Oct 16, 2024 |
| Cormorant Asset Management, LP | -- | Purchase | 7.2K | $171.8K | Oct 16, 2024 |
| Cormorant Asset Management, LP | -- | Purchase | 3.1K | $78.4K | Oct 16, 2024 |
| Cormorant Asset Management, LP | -- | Purchase | 2.7K | $25.0K | Oct 15, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
Ian McDonald · may incl. warrants· filed Jul 2026 | 1.4M | 14.2% | 13D |
Jupiter Topco LLC | 1.3M | 13.7% | 13F |
JANUS HENDERSON GROUP PLC · may incl. warrants· filed May 2026 | 1.3M | 13.0% | 13G |
Cormorant Asset Management, LP · also on 13F· joint filing· may incl. warrants· filed Apr 2026 | 950.0K | 9.6% | 13G |
Cormorant Asset Management, LP | 900.0K | 9.1% | 13F |
BlackRock, Inc. | 686.2K | 7.0% | 13F |
Vivo Capital, LLC | 557.2K | 5.6% | 13F |
Vestal Point Capital, LP | 545.0K | 5.5% | 13F |
Vivo Opportunity Fund Holdings, L.P. · also on 13F· joint filing· may incl. warrants· filed May 2026 | 504.6K | 5.1% | 13G |
BRAIDWELL LP | 483.8K | 4.9% | 13F |
Insiders
based on 9.86M shares outstanding
CA30d Avg
152.75K
60d Avg
120.84K
90d Avg
137.42K